Access Investment Management LLC Acquires Shares of 194,715 Integra LifeSciences Holdings Co. (NASDAQ:IART)

Access Investment Management LLC purchased a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 194,715 shares of the life sciences company's stock, valued at approximately $4,416,000. Integra LifeSciences comprises approximately 1.3% of Access Investment Management LLC's portfolio, making the stock its 28th biggest holding. Access Investment Management LLC owned approximately 0.25% of Integra LifeSciences as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the business. KBC Group NV raised its holdings in Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock worth $52,000 after purchasing an additional 1,120 shares during the period. New York State Teachers Retirement System raised its stake in shares of Integra LifeSciences by 3.0% in the third quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company's stock worth $1,637,000 after buying an additional 2,616 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after buying an additional 2,800 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of Integra LifeSciences by 4.1% during the 4th quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company's stock valued at $2,919,000 after acquiring an additional 5,032 shares during the period. Finally, Choreo LLC increased its holdings in Integra LifeSciences by 29.9% in the 4th quarter. Choreo LLC now owns 22,274 shares of the life sciences company's stock worth $500,000 after acquiring an additional 5,123 shares in the last quarter. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Price Performance

IART traded down $1.12 during trading on Wednesday, reaching $23.60. 992,944 shares of the company traded hands, compared to its average volume of 611,115. The company has a market cap of $1.82 billion, a P/E ratio of -262.19, a PEG ratio of 0.73 and a beta of 1.17. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $44.69. The firm has a fifty day simple moving average of $23.71 and a 200 day simple moving average of $21.83.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.12. The company had revenue of $442.65 million during the quarter, compared to analysts' expectations of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences's quarterly revenue was up 11.5% on a year-over-year basis. During the same period last year, the company posted $0.89 earnings per share. On average, equities analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Morgan Stanley started coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They set an "underweight" rating and a $20.00 price target on the stock. Citigroup lifted their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $23.00.

Insider Transactions at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the transaction, the executive vice president now directly owns 56,182 shares of the company's stock, valued at approximately $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.10% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.